While OS is still the king of the oncology endpoints, experts note it may soon be phased out due to the introduction of ...

Enanta Pharmaceuticals remains a Buy as zelicapavir shows promise in RSV trials; strong financials support growth. Read why ...

Join our daily and weekly newsletters for the latest updates and exclusive content on industry-leading AI coverage. Learn More Attackers are turning to generative AI to hunt for the easiest endpoints ...

In this video interview, Ananth Kadambi, VP of real-world evidence and modeling solutions at Certara, outlines how FDA’s ...

Endpoint protection, often abbreviated as EPP, is a system designed to secure each endpoint of an enterprise network from potential cyber threats. It's a security approach that focuses on each device ...

Enata Pharmaceuticals said it didn't meet its primary endpoint in a Phase 2b study of zelicapavir, its proposed treatment for Respiratory Syncytial Virus, or RSV, in high-risk adults.

Kala Bio missed the primary endpoint in the study for its treatment of Persistent Corneal Epithelial Defect, an eye defect, and said it would stop development of the drug, called KPI-012. The company ...

Kura Oncology (KURA) and Kyowa Kirin announced the Journal of Clinical Oncology published the full results from the pivotal ...

Join the event trusted by enterprise leaders for nearly two decades. VB Transform brings together the people building real enterprise AI strategy. Learn more Bad actors continue to capitalize on the ...

Investing.com -- Enanta Pharmaceuticals (NASDAQ:ENTA) stock fell 14% after the company announced that its experimental drug zelicapavir failed to meet the primary endpoint in a Phase 2b study for ...